Solbec has been undervalued for a while now. Cancer and psoriasis both successful in phase I trials and the company is moving towards phase II in both these multi-billion dollar markets. The drug has been shown to stimulate immunity towards cancer and preclinical studies continue in this area with results expected in a month or two. This only adds to the excitement building towards Coramsine. There is also growing interest from overseas and one would expect news of a partnership agreement with a big pharam sooner rather than later.
SBP Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
